Immunoassay Method Validation: Regulatory Guidance and Best Practices

Immunoassay method validation is the documented process of demonstrating that an assay performs reliably for its intended use, with accuracy, precision, specificity, and sensitivity established under defined conditions. For laboratory students, technicians, researchers, and diagnostic professionals, validation is a regulatory requirement before patient samples can be tested, and it applies to commercial kits, laboratory-developed tests, and modified approved assays alike. The Clinical Laboratory Improvement Amendments (CLIA) federal regulatory standards require clinical laboratories to establish and document their own performance specifications for laboratory-developed tests to ensure accurate and precise results prior to implementation of the test, with performance characteristics including accuracy, precision, reportable range, reference interval, analytical sensitivity, and analytical specificity [6]. This article provides a practical framework for planning, executing, and documenting immunoassay validation aligned with regulatory expectations from the U.S. Food and Drug Administration (FDA) and the International Council for Harmonisation (ICH).

Scope and Regulatory Context

Validation requirements differ depending on whether an immunoassay is a commercial FDA-cleared kit used exactly as intended, a modified version of an approved assay, or a laboratory-developed test. The FDA Bioanalytical Method Validation Guidance for Industry describes the expectations for bioanalytical methods used in nonclinical and clinical studies, including ligand binding assays commonly used for immunoassay work [4]. The World Health Organization Laboratory Quality Management System Handbook provides a broader framework for quality assurance across the entire testing process, from pre-analytical through post-analytical phases [1]. The National Center for Advancing Translational Sciences Assay Guidance Manual offers detailed technical recommendations for assay development and validation in translational research settings [3].

For clinical diagnostic laboratories, CLIA regulations establish the baseline requirement to verify or establish performance specifications before reporting patient results. The Clinical Microbiology Reviews paper on validation of laboratory-developed molecular assays explains that laboratories often modify FDA-approved assays to include different extraction systems or additional specimen types, and in those cases the laboratory must establish performance characteristics for the modified method [6]. The same principle applies to immunoassays, where reagent lot changes, instrument changes, or specimen type extensions trigger verification or validation activities.

The vaccine industry has identified a lack of clarity in regulatory guidance for vaccine immunoassay validation, leading to harmonization efforts through the Workshop on Recent Issues in Bioanalysis (WRIB) White Paper process, which brings together industry leaders and regulators to develop consensus recommendations [12]. This illustrates that even in regulated industries, interpretation of validation requirements evolves through collaborative efforts, and laboratories should stay current with emerging guidance.

Core Validation Parameters

Validation of an immunoassay requires systematic evaluation of multiple analytical parameters. The FDA Bioanalytical Method Validation Guidance describes the expectations for accuracy, precision, selectivity, sensitivity, reproducibility, and stability for ligand binding assays [4]. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides additional technical detail on experimental designs for each parameter [3].

Accuracy and Bias

Accuracy describes the closeness of agreement between the measured value and the true value of the analyte. In immunoassay validation, accuracy is typically assessed by measuring quality control samples with known concentrations, comparing results to a reference method, or performing recovery studies where known amounts of analyte are spiked into a sample matrix. The methotrexate immunoassay validation study demonstrated accuracy assessment through method comparison, where the Roche assay showed a mean percentage difference of -12% compared to the ARK assay and -18% compared to LC-MS/MS [8]. This illustrates that accuracy is often expressed as percent bias relative to a comparator method.

Precision

Precision describes the closeness of agreement between repeated measurements of the same sample. Precision is evaluated at multiple levels, including within-run (repeatability), between-run, and between-day (intermediate precision). The MeMed-BV validation study reported acceptable intra- and inter-assay precision with a range of less than 3 score units in both high-score bacterial and low-score viral controls [11]. The methotrexate assay validation reported coefficients of variation for precision below 10% [8]. The ICH Q2(R2)-aligned proteomics validation demonstrated that repeatability dominated the variance structure with a median CV of 2.7%, while intermediate precision standard deviation ranged from 0.69% to 3.81% [16].

Analytical Sensitivity

Analytical sensitivity refers to the lowest concentration of analyte that can be reliably detected or quantified. The limit of detection (LOD) is the lowest concentration distinguishable from a blank, while the lower limit of quantification (LLOQ) is the lowest concentration that can be measured with acceptable accuracy and precision. The methotrexate LC-MS/MS method achieved an LLOQ of 0.01 µmol/L, while the immunoassay was linear across the analytical measurement interval of 0.04-1.2 µmol/L [8,14]. The fentanyl test strip validation demonstrated detection at 200 ng/ml in water for fentanyl and 13 additional fentanyl analogs, but failed to detect carfentanil and furanyl fentanyl at or below 1000 ng/ml [10].

Analytical Specificity

Analytical specificity describes the ability of the assay to measure the intended analyte without interference from other substances. Interference can come from structurally related compounds, metabolites, endogenous substances, or matrix components. The methotrexate immunoassay comparison study found that immunoassays exhibited biases related to cross-reactivity with MTX metabolites such as DAMPA and 7-OH-MTX, which may lead to overestimation of MTX levels [14]. The MeMed-BV validation found that gross hemolysis and icterus did not affect the assay, but gross lipemia showed considerable bias in samples with moderate likelihood of viral infection [11].

Reportable Range and Linearity

The reportable range is the span of analyte concentrations over which the assay produces accurate results without dilution or concentration. Linearity describes whether the measured values are proportional to the true concentrations across this range. The methotrexate assay was linear across the analytical measurement interval of 0.04-1.2 µmol/L, and automatic and manual dilutions demonstrated less than 10% bias [8]. The fentanyl test strip study demonstrated that false positives occurred when fentanyls were present below 40 ng/ml, illustrating the importance of defining the reliable detection range [10].

Reference Interval

The reference interval is the range of values expected in a healthy or defined population. This parameter must be established or verified for each assay and population. The CLIA requirements described in the molecular assay validation review include reference interval as one of the performance characteristics that must be established [6]. Reference intervals may need to be verified for different age groups, sexes, or clinical populations.

At a Glance

Validation Protocol Development

A validation protocol is a written document that defines the scope, responsibilities, experimental design, acceptance criteria, and documentation requirements for the validation study. The protocol should be approved before validation begins and should reference the relevant regulatory guidance documents.

Protocol Components

The validation protocol should include a statement of purpose, description of the assay and its intended use, list of materials and equipment, detailed experimental procedures for each parameter, predefined acceptance criteria, and a plan for data analysis and documentation. The World Health Organization Laboratory Quality Management System Handbook emphasizes the importance of documented procedures and records throughout the laboratory quality system [1].

The protocol should specify the number of runs, replicates, and concentration levels for each experiment. For precision studies, the protocol should define the number of days, runs per day, and replicates per run. For accuracy studies, the protocol should specify the reference method or materials used and the number of samples tested.

Acceptance Criteria

Acceptance criteria should be defined before validation begins and should be based on the intended use of the assay. A quantitative immunoassay used for therapeutic drug monitoring may require tighter acceptance criteria than a qualitative screening assay. The methotrexate assay validation reported coefficients of variation for precision and percentage bias for accuracy below 10% [8]. The fentanyl test strip study reported overall sensitivity of 98.5% and specificity of 89.2% for detecting fentanyls, with false negative and positive rates of 1.5% and 10.9% [10].

Documentation Requirements

Validation documentation should include the approved protocol, raw data, data analysis, summary report, and records of any deviations from the protocol. The World Health Organization Laboratory Quality Management System Handbook describes the importance of records that allow reconstruction of the testing process and verification of the validity of results [1]. The validation report should state whether acceptance criteria were met, describe any deviations, and document the final decision on assay implementation.

Practical Validation Workflow

The validation workflow proceeds through defined stages from planning to implementation. Each stage requires specific decisions and documentation.

Stage 1: Define the Intended Use

The intended use statement defines what the assay will measure, in what specimen type, for what clinical purpose, and in what population. This statement drives all subsequent validation decisions. An assay intended for diagnosis of acute infection may require different performance characteristics than an assay intended for monitoring treatment response. The histoplasmosis review describes how antigen detection is the most sensitive method for diagnosis, with sensitivity of 95-100% in urine, over 90% in serum and bronchoalveolar lavage, and 78% in cerebrospinal fluid [7]. This illustrates that the same analyte may perform differently across specimen types, and the intended use must specify which specimen types are validated.

Stage 2: Select Materials and Equipment

The validation requires defined reagents, calibrators, controls, and equipment. Reagent lot numbers, expiration dates, and storage conditions must be documented. The equipment used for validation should be the same equipment that will be used for routine testing, or the validation should include an instrument-to-instrument comparison. The methotrexate assay was validated on Cobas c502 and Cobas pro c503 platforms across two clinical sites, demonstrating that multi-site and multi-instrument validation is feasible [8].

Stage 3: Execute the Validation Experiments

The validation experiments should follow the approved protocol exactly. Any deviation must be documented and assessed for impact on the validation. The experiments should be performed by the personnel who will perform routine testing, using the same procedures and conditions.

Stage 4: Analyze Data and Compare to Acceptance Criteria

Data analysis should be performed using predefined statistical methods. The results should be compared to the acceptance criteria defined in the protocol. The ICH Q2(R2)-aligned proteomics validation used total-error analysis with 95% beta-expectation and 95/95 content tolerance intervals contained within plus or minus 30% at all levels [16]. This approach illustrates how modern validation studies use total-error frameworks that combine accuracy and precision into a single assessment.

Stage 5: Write the Validation Report

The validation report summarizes the protocol, results, data analysis, and conclusions. The report should state whether the assay met all acceptance criteria and whether the assay is suitable for its intended use. The report should be reviewed and approved by laboratory leadership before the assay is implemented for routine testing.

Stage 6: Implement the Assay with Ongoing Quality Control

After validation, the assay enters routine use with ongoing quality control. Quality control samples are tested with each run, and results are monitored for trends or shifts. The World Health Organization Laboratory Quality Management System Handbook describes the importance of internal quality control and external quality assessment as ongoing components of the quality system [1].

Options and Tradeoffs in Validation Design

Different validation approaches have different strengths and limitations. The choice of approach depends on the assay type, available resources, and regulatory requirements.

Commercial Kit Verification versus Full Validation

For FDA-cleared commercial kits used exactly as intended, laboratories may perform verification instead of full validation. Verification typically includes accuracy, precision, and reference interval verification using a smaller number of samples. For laboratory-developed tests or modified approved assays, full validation is required. The molecular assay validation review explains that CLIA requires laboratories to establish and document their own performance specifications for laboratory-developed tests [6].

Method Comparison versus Recovery Studies

Accuracy can be assessed through method comparison with a reference method or through recovery studies using spiked samples. Method comparison provides information about how the new assay performs relative to an established method across the measuring range. The methotrexate assay validation used method comparison with 40 patient samples, showing strong correlation with a Deming regression slope of 0.9634 and Pearson correlation coefficient of 0.9935 [8]. Recovery studies provide information about the assay performance in the specific sample matrix.

Single-Site versus Multi-Site Validation

Multi-site validation provides information about assay performance across different laboratories, instruments, and operators. The methotrexate assay was validated across two clinical sites [8]. The RSV multiplex immunoassay was technically validated to standard FDA bioanalytical guidelines and clinically validated using samples from human challenge studies [9]. Multi-site validation increases confidence in assay robustness but requires more resources and coordination.

Quantitative versus Qualitative Validation

Quantitative immunoassays require validation of accuracy, precision, sensitivity, specificity, and reportable range with numeric acceptance criteria. Qualitative immunoassays require validation of sensitivity, specificity, and agreement with a reference method, often expressed as percent agreement. The fentanyl test strip validation reported sensitivity and specificity for a qualitative lateral flow assay [10]. The MeMed-BV validation reported diagnostic sensitivity of 94% and specificity of 88% for identifying bacterial infections or co-infections [11].

Records and Measurements

Accurate records are essential for demonstrating regulatory compliance and for troubleshooting assay problems. The World Health Organization Laboratory Quality Management System Handbook emphasizes that records must be legible, permanent, and retrievable [1].

Required Records

Validation records should include the approved protocol, reagent and control lot numbers, equipment calibration records, raw data including instrument printouts and worksheets, data analysis files, and the final validation report. Any deviations from the protocol should be documented with the reason for the deviation and the impact assessment.

Quality Control Records

After implementation, quality control records should include daily QC results, lot-to-lot verification records, and corrective action documentation when QC failures occur. The World Health Organization Laboratory Quality Management System Handbook describes the importance of internal quality control for monitoring the precision and accuracy of the testing process over time [1].

Measurement Units and Traceability

Results should be reported in defined units with traceability to reference materials where available. The methotrexate assays reported results in µmol/L [8,14]. The aldosterone immunoassay was tailored to GCLP-compliant investigations in small sample volumes, illustrating the importance of matching assay design to the sample volume available [19].

Common Failure Patterns

Understanding common validation failures helps laboratories design better protocols and troubleshoot problems when they occur.

Cross-Reactivity and Interference

Cross-reactivity with structurally related compounds is a common cause of immunoassay inaccuracy. The methotrexate immunoassay comparison found that immunoassays exhibited biases related to cross-reactivity with MTX metabolites such as DAMPA and 7-OH-MTX, which may lead to overestimation of MTX levels and unnecessary prolongation of leucovorin rescue [14]. This finding illustrates that even well-established immunoassays can have clinically significant cross-reactivity, and validation should include testing of known metabolites and structurally related compounds.

Matrix Effects

The sample matrix can interfere with immunoassay performance. The MeMed-BV validation found that gross lipemia showed considerable bias in samples with moderate likelihood of viral infection, while hemolysis and icterus did not affect the assay [11]. Matrix effects can vary by specimen type, and validation should include testing of the intended specimen types with a range of matrix conditions.

Lot-to-Lot Variability

Reagent lot changes can affect assay performance. Laboratories should verify performance when changing reagent lots, and the verification should include at least accuracy and precision assessment. The World Health Organization Laboratory Quality Management System Handbook describes the importance of verifying that new reagent lots perform acceptably before they are used for patient testing [1].

Hook Effect

The hook effect occurs when very high concentrations of analyte saturate the assay reagents, causing falsely low results. This is a particular concern for sandwich immunoassays. Validation should include testing of high-concentration samples to ensure that the assay does not exhibit a hook effect within the expected clinical range.

Insufficient Sample Volume

Some immunoassays require minimum sample volumes that may be difficult to obtain from certain patient populations. The aldosterone immunoassay was specifically tailored to GCLP-compliant investigations in small sample volumes [19]. Validation should include assessment of the minimum sample volume required for reliable results.

Quality Controls and Ongoing Monitoring

Ongoing quality control is essential after validation to ensure that the assay continues to perform as validated. The World Health Organization Laboratory Quality Management System Handbook describes the components of a comprehensive quality system, including internal quality control and external quality assessment [1].

Internal Quality Control

Internal quality control involves testing control samples with each run or batch of patient samples. Control results are monitored against defined acceptance criteria, and runs are rejected if controls fail. The MeMed-BV validation used high-score bacterial and low-score viral controls to monitor assay performance [11].

External Quality Assessment

External quality assessment, also known as proficiency testing, involves testing unknown samples provided by an external organization and comparing results with other laboratories. Participation in external quality assessment programs provides an independent assessment of assay performance. The World Health Organization Laboratory Quality Management System Handbook describes external quality assessment as a component of the quality system [1].

Lot-to-Lot Verification

When a new reagent lot is received, the laboratory should verify that the new lot performs acceptably before it is used for patient testing. The verification should include at least accuracy and precision assessment using quality control samples and, where possible, patient samples tested with both the old and new lots.

Biosafety Considerations

Immunoassay validation involves handling of biological samples, including potentially infectious materials. The World Health Organization Laboratory Biosafety Manual provides guidance on safe handling of biological materials in the laboratory [2]. Validation studies should follow the same biosafety practices as routine testing, including appropriate personal protective equipment, containment, and waste disposal.

Sample Handling

Patient samples used for validation should be handled as potentially infectious. This includes serum, plasma, urine, cerebrospinal fluid, and other body fluids. The World Health Organization Laboratory Biosafety Manual describes the principles of biosafety for laboratory work with biological materials [2].

Reagent Safety

Immunoassay reagents may contain hazardous materials, including preservatives, radioactive labels, or enzymes. Material safety data sheets should be reviewed, and appropriate handling procedures should be followed. The World Health Organization Laboratory Biosafety Manual provides guidance on safe handling of laboratory chemicals [2].

Waste Disposal

Biological waste and reagent waste should be disposed of according to institutional and regulatory requirements. The World Health Organization Laboratory Biosafety Manual describes appropriate waste management practices for laboratories [2].

Professional Escalation Criteria

Laboratory personnel should know when to escalate validation problems to supervisors, laboratory directors, or other appropriate authorities.

Escalation for Validation Failures

If validation experiments fail to meet acceptance criteria, the laboratory should escalate the issue to the laboratory director or validation team leader. The escalation should include a description of the failure, the data supporting the failure, and any preliminary investigation findings. The laboratory director should determine whether the protocol needs revision, whether the assay needs redesign, or whether the assay should be abandoned.

Escalation for Unexpected Results

If validation results show unexpected patterns, such as nonlinearity, inconsistent precision, or unexpected interference, the laboratory should escalate the issue for investigation. The investigation may require consultation with the reagent manufacturer, reference laboratory, or regulatory authority.

Escalation for Safety Concerns

If validation activities reveal safety concerns, such as unexpected infectious exposure or reagent hazards, the laboratory should escalate the issue immediately to the biosafety officer or institutional safety committee. The World Health Organization Laboratory Biosafety Manual describes the importance of reporting and investigating laboratory incidents [2].

Limitations of Immunoassay Validation

Validation demonstrates that an assay performs acceptably under defined conditions, but it has inherent limitations that laboratories should understand.

Population-Specific Performance

Validation studies typically use samples from a defined population, and performance may differ in other populations. The MeMed-BV validation was conducted in a pediatric cohort, and the results may not apply to adult populations [11]. The histoplasmosis antigen assay showed different sensitivity across specimen types, with 95-100% in urine, over 90% in serum and bronchoalveolar lavage, and 78% in cerebrospinal fluid [7].

Evolving Analytical Methods

Immunoassay technology continues to evolve, and new methods may offer improved performance. The methotrexate comparison study concluded that while immunoassays remain practical for routine monitoring due to their accessibility and speed, LC-MS/MS provides superior accuracy and should be the method of choice in critical clinical situations [14]. Laboratories should periodically evaluate whether newer methods offer meaningful improvements for their clinical applications.

Regulatory Guidance Evolution

Regulatory guidance for immunoassay validation continues to evolve. The vaccine industry harmonization efforts through the WRIB White Paper process illustrate how validation recommendations develop through collaboration between industry and regulators [12]. Laboratories should stay current with emerging guidance and update their validation practices accordingly.

Commercial Assay Quality Variation

The quality of commercial immunoassays varies, and validation is essential even for commercially available assays. The relaxin-2 immunoassay review noted that validation of commercial assays is often lacking or completely absent, and data derived from these assays must be questioned if the investigator does not supply information on the validation of the assay used [13]. This finding emphasizes that laboratories bear the ultimate responsibility to demonstrate that an assay is valid for the stated claims.

Frequently Asked Questions

What is the difference between verification and validation of an immunoassay?

Verification is the process of confirming that an FDA-cleared or approved assay performs as claimed when used exactly as intended by the manufacturer. Verification typically includes accuracy, precision, and reference interval confirmation using a limited number of samples. Validation is the process of establishing performance specifications for a laboratory-developed test or a modified approved assay. Validation requires more extensive experiments to establish accuracy, precision, sensitivity, specificity, reportable range, and reference interval. CLIA regulations require laboratories to establish and document their own performance specifications for laboratory-developed tests [6].

How many samples are needed for immunoassay validation?

The number of samples needed depends on the assay type, the validation parameter being assessed, and the acceptance criteria. Precision studies typically require multiple replicates across multiple runs and days. Method comparison studies require enough samples to cover the reportable range and to allow meaningful statistical analysis. The methotrexate assay validation used 40 patient samples for method comparison [8]. The MeMed-BV clinical performance assessment used a retrospective cohort of 60 pediatric patients [11]. The validation protocol should specify the sample numbers based on the statistical power needed to meet acceptance criteria.

What acceptance criteria should be used for immunoassay validation?

Acceptance criteria should be defined in the validation protocol before experiments begin and should be based on the intended use of the assay. Quantitative assays often use acceptance criteria of less than 15-20% for precision and accuracy. The methotrexate assay validation reported coefficients of variation for precision and percentage bias for accuracy below 10% [8]. Qualitative assays use sensitivity and specificity criteria, such as the 98.5% sensitivity and 89.2% specificity reported for the fentanyl test strip [10]. The ICH Q2(R2)-aligned proteomics validation used total-error limits of plus or minus 30% [16].

How should interference from hemolysis, lipemia, and icterus be evaluated?

Interference studies should test samples with varying levels of hemolysis, lipemia, and icterus to determine whether these conditions affect assay results. The MeMed-BV validation found that gross hemolysis and icterus did not affect the assay, but gross lipemia showed considerable bias in samples with moderate likelihood of viral infection [11]. Interference testing should include samples at clinically relevant analyte concentrations, and the results should be compared to acceptance criteria for bias.

What is the hook effect and how is it evaluated?

The hook effect occurs when very high concentrations of analyte saturate the assay reagents, causing falsely low results. This is a particular concern for sandwich immunoassays. The hook effect is evaluated by testing samples with very high analyte concentrations and verifying that the measured values continue to increase or plateau instead of decrease. Validation should include testing of high-concentration samples to ensure that the assay does not exhibit a hook effect within the expected clinical range.

How often should immunoassay validation be repeated?

Validation is repeated when there are significant changes to the assay, including changes to reagents, instruments, specimen types, or testing procedures. Reagent lot changes typically require verification instead of full validation. The World Health Organization Laboratory Quality Management System Handbook describes the importance of verifying that new reagent lots perform acceptably before they are used for patient testing [1]. Major changes to the assay method or instrumentation may require full revalidation.

What documentation is required for regulatory compliance?

Documentation should include the approved validation protocol, raw data, data analysis, validation report, and records of any deviations. The World Health Organization Laboratory Quality Management System Handbook emphasizes that records must be legible, permanent, and retrievable [1]. The validation report should state whether acceptance criteria were met, describe any deviations, and document the final decision on assay implementation. Ongoing quality control records should be maintained after implementation.

How should validation results be used to make decisions about assay implementation?

Validation results should be compared to the predefined acceptance criteria in the protocol. If all acceptance criteria are met, the assay can be implemented for routine testing. If any acceptance criteria are not met, the laboratory should investigate the cause and determine whether the assay can be modified and revalidated or whether it should not be implemented. The validation report should document the decision and the rationale. The relaxin-2 immunoassay review noted that the end user bears the ultimate responsibility to demonstrate that the assay is valid for the stated claims [13].

Related Diagnostic Guides

• Drop Plate Method for Viable Cell Counting: Protocol and Best Practices
• RNA Extraction Using TRIzol Reagent: Protocol, Troubleshooting, and Best Practices
• Lowry Assay Protocol: Protein Quantification Method
• qPCR Data Normalization: Methods and Best Practices
• Spread Plate Method: Protocol, Advantages, and Applications

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Validation of laboratory-developed molecular assays for infectious diseases.. Clinical microbiology reviews, 2010.
• HIV-Associated Histoplasmosis: Current Perspectives.. HIV/AIDS (Auckland, N.Z.), 2020.
• Multi-Site Validation of a Newly FDA-Cleared Automated Methotrexate Immunoassay for Therapeutic Drug Monitoring.. The journal of applied laboratory medicine, 2026.
• Development and validation of a respiratory syncytial virus multiplex immunoassay.. Infection, 2024.
• Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples.. Drug and alcohol dependence, 2022.
• Validation of a multi-analyte immunoassay for distinguishing bacterial vs. viral infections in a pediatric cohort.. Clinica chimica acta, international journal of clinical chemistry, 2023.
• Harmonization of Vaccine Ligand Binding Assays Validation.. Bioanalysis, 2024.
• Commercial immunoassays for human relaxin-2.. Molecular and cellular endocrinology, 2019.
• Novel LC-MS/MS method for measuring methotrexate in high-dose therapy: a comparative study with commercial EMIT and EIA immunoassays.. 2026.
• Meta-Analytic Modeling to Define Decision Thresholds for Cerebrospinal Fluid Heparin-Binding Protein in Healthcare-Associated Ventriculitis and Meningitis.. 2026.
• Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics.. 2026.
• 25 years of applying the 3Rs principles in safety pharmacology: success stories and future perspectives.. 2026.
• Validation of Romer Labs RapidChek® Listeria monocytogenes NextDay™ Plus Test System for the Detection of Listeria monocytogenes on Select Food Matrices and Environmental Surfaces: AOAC Performance Tested MethodSM 042501.. Journal of AOAC International, 2026.
• Validated low-volume aldosterone immunoassay tailored to GCLP-compliant investigations in small sample volumes. Practical Laboratory Medicine, 2017.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.